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Background
Single-use (SU) technologies supply a number of values
to any mode of bioprocessing, but can provide some
specific and enabling features in continuous bioprocessing
(CB) implementations [1-3]. Most every operation in a CB
process train is now supported by a commercially available
single-use, or at least hybrid, solution (Figure 1). First
of all, many of the SU equipment and solutions being
developed for batch bioproduction have the same or
related application in CB systems. Examples here include
simple equipment such as tubings and connectors, to
more complex applications such as the cryopreservation
of large working stock aliquots in flexible bioprocess
containers (BPCs). The list of CB-supporting SU tech-
nologies being developed is large and growing.
Results
A SU advantage in process development is its supports
of an open architecture approach and a number of
hybrid designs. Such designs include combining reusable
and single-use systems, or between divergent suppliers
of particular equipment. Especially in bioproduction, the
many flexibilities of SU support a manufacturing platform
of exceptional efficiency, adaptability, and operational
ease. Advances designs in SU transfer tubing, manifold
design and container porting also supports creativity in
process design. This is of particular value in designing a
process with such demands as entirely new flow paths or
lot designations, such for CB.
SU systems upstream provide a reduced footprint and
eliminate of the need for cleaning and sterilization service.
This complements perfusion culture’s inherently smaller
size and independence from cleaning for extended periods
of time.
Several newer approaches to formulating process fluids
support the concept of CB. Single-use mixing systems are
typically constructed of a rigid containment system with a
motor and controls driving radiation-sterilized single-use
bags equipped with disposable impeller assemblies. From
a variety of manufacturers there are a number of distinct
approaches to motor/disposable impeller assembly
linkages, tubing lines and connections. Also appearing are
a number of exciting SU sampling, sensing, and monitor-
ing solutions. Single-use powder containers permit seam-
less transfer between powder and liquid formulation steps,
and the ridged mixing containers are available in jacketed
stainless steel for heating and cooling requirements.
Surprisingly, the “topping-up” of large-scale single-use
fluid containers with newly prepared buffer to provide a
virtually unlimited and constant supply of each buffer/
media type can be validated for GMP manufacturing
procedures.
Process flexibility is a key feature in both SU and CB.
CB contributes to overall process flexibility in that equip-
ment tends to be easy to clean, inspect and maintain −
and generally promotes simple and rapid product change-
over. SU systems can provide similar flexibility and ease
product changeover because they tend to be more modu-
lar and transportable than much of the older batch equip-
ment. In fact the size, configuration and reduced service
requirements of SU systems actually encourage diversity
of physical location within a suite or plant, as well as
re-location to other manufacturing sites.
Due to its inherent demand for immediate process data
and control capabilities, CB supports initiatives in continu-
ous quality verification (CQV), continuous process verifi-
cation (CPV), and real-time release (RTR). Although CB
will not be feasible for all products and processes, many
implementations well-support a “platform” approach,
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in which a single process supports more than one product.
CB most always shortens the process stream, reduces
downtime, and greatly reduces handling of intermediates.
These features complement the operational efficiencies of
SU systems, contributing to a greatly reduced cumulative
processing time for the API. Furthermore, they greatly
simplify production trains and inherently facilitate appli-
cation of closed processing approaches to individual
operations and even processes. Especially in bioproduc-
tion, the modularity and integral gamma irradiation steri-
lity of SU combined with the sustained operation of CB
promise the appearance of platforms of unparalleled
operational simplicity and convenience.
The heart of a CB approach is the bioreactor. Perfusion
bioreactors have been successfully employed in bioproduc-
tion, even biopharmaceutical production, for decades.
And, rather remarkably, disposable bioreactors have been
available for nearly 20 years. At the research scale there
have even been single-use hollow fiber perfusion bioreac-
tors available from a variety of vendors for over 40 years.
However, only recently have commercially available SU
and hybrid production-scale perfusion-capable equipment
become available.
The production-scale CB enabling SU bioreactor tech-
nologies now becoming commercial available include
single-use and hybrid perfusion-capable reactors (Figure 1);
a growing variety of SU and hybrid monitoring probes
and sensors; SU pumps and fluid delivery automation of
various design; and automated SU online sampling,
interface, valving and feeding technologies. Their coordi-
nated implementation in actual production settings with
appropriate control is now beginning.
Justified or not, concerns in the implementation of
CB include performance reliability (incidence of failure),
validation complexity, process control and economic
justification. But for many processes, such previous
limitations – or their perception – are being alleviated
by advances in CB processing technology and OpEx driven
advances bioprocess understanding, reactor monitoring
and feedback control. However, while some CB attributes
inherently provide immediate advantages (such as reduces
reactor residency time) others do present challenges (such
as cell-line stability concerns).
Due to the limited contribution of API manufacturing
to small-molecule pharmaceutical cost, the limited
bottom-line financial savings of CB has been a concern.
Figure 1 Hybrid intensified perfusion-based continuous bioproduction in a Thermo Scientific HyPerforma S.U.B. TK 250L supported by
yhe Refine Technology ATF System.
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However, biopharma is a different animal in general,
and as such trends as globalization and biosimilars alter
the picture even further, the financial benefits of CB are
becoming even stronger.
The fact that many SU systems are constructed of
standards compliant and animal product-free materials
supports CB applications in a wide variety of product
types and classification. In fact, SU systems are available
to most any process format (eg, microcarriers and sus-
pension), platform (eg, cell line, vectors, culture media),
mode (eg, dialysis or enhanced perfusion) or scale (eg,
through rapid, inexpensive scale-out). “Futureproofing”,
or supporting the sustainability of a new CB process in
the face of product lifecycle or emerging technology
imperative, is supported by many SU features. Examples
here include SUs low initial facility, service and equipment
cost and especially SU’s undedicated manufacturing suits
and ease of process train reconfiguration.
Conclusion
As advanced single-use solutions are applied to single-use
perfusion mode-capable reactors, the design of integrated
closed, disposable and continuous upstream bioproduction
systems are finally being realized.
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